Cencora (NYSE:COR) Q1 2024 Earnings Call Transcript

Thanks.

Operator: Our next question comes from George Hill with Deutsche Bank. Your line is open. Please go ahead.

George Hill: Hey guys, thanks for squeezing me in and I’m going to kind of get into a niche topic here with CenterX, Jim. I know that you guys have that EPA business and we’ve seen kind of a surge in demand for EPAs, both as it relates to GLP-1s and the increasing use of biosimilars. So we’d just love to hear you talk a little bit about how that business is performing relative to kind of the GLP-1s in the biosimilar space.

Jim Cleary: Yes. So I’ll say, overall, we feel really good about our prospects in global pharma services and patient services and the sorts of things that CenterX does. And we feel just very good overall about the growth prospects there and really don’t have any comments beyond that other than to say kind of global pharma services. And those businesses like CenterX are just a key part of our growth this year and over our long-term guidance also.

Operator: This concludes our Q&A. I’ll hand back to Steve Collis.

Steve Collis: Thanks, everyone. I appreciate your patience. We ran a little bit long today. So this wraps up our call for today. I just have to make a little note that at the end of our fiscal year 2023 call, I received a little pouch and it was 50 quarters from my predecessor to commemorate 50 earnings calls. So once we’re counting, 51 is clearly one of the most memorable and exciting quarters that we have presented, and even more so to do it under the new call ticker symbol. While we have a lot of work ahead to continue to deliver on our purpose and the potential of Cencora, we are really proud of the work our team members are doing to position us successfully and strategically at the center of pharmaceutical based healthcare. Thank you for your time today.

Operator: Ladies and gentlemen, this call has now concluded.